UGN-101(丝裂霉素反热凝胶)对低级别上尿路尿路上皮癌原发化学消融的长期结局
该研究评估UGN-101对低级别上尿路尿路上皮癌原发化学消融的长期结局。OLYMPUS试验中71例患者有42例达完全缓解,41例随访中位28.1个月,中位缓解持续时间47.8个月,末次随访75%无复发证据。结论认为该治疗具有有利的长期持久性。
要点
- OLYMPUS试验71例中42例在UGN-101治疗后达完全缓解。
- 41例随访者中位随访28.1个月,中位缓解持续时间47.8个月。
- 末次随访75%无复发证据,因事件率低中位缓解持续时间不可估计。
核心结论
- 低级别上尿路尿路上皮癌原发腔内UGN-101化学消融与有利的长期持久性相关。
研究设计与样本
- OLYMPUS试验(IRB编号TC-UT-03,NCT02793128)中接受6次每周UGN-101剂量后达完全缓解的患者随访至初始完全缓解后12个月。
- 研究完成时仍完全缓解者进入长达5年或直至疾病复发、进展或死亡的长期随访。
主要发现
- OLYMPUS试验入组71例,42例在完成至少1次UGN-101灌注后4至6周达完全缓解。
- 初始完全缓解后随访的41例中,中位随访28.1个月(95%CI 13.1-57.5),中位缓解持续时间47.8个月(95%CI 13.0-不可估计[NE])。
- 20例(49%)接受长期随访(中位53.3个月[95%CI 27.9-65.3])。
- 末次随访时75%患者无复发证据,因事件率低中位缓解持续时间不可估计(95%CI 43.5-不可估计)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluate long-term outcomes of primary chemoablation using a mitomycin reverse thermal gel (UGN-101) in patients with low-grade upper tract urothelial carcinoma. MATERIALS AND METHODS: Patients who participated in the OLYMPUS trial (IRB No. TC-UT-03, NCT02793128) and achieved a complete response (CR) after 6 weekly doses of UGN-101 were followed up to 12 months after initial CR. Those with CR at study completion were eligible for long-term follow-up for up to 5 years or until disease recurrence, progression, or death. RESULTS: Of the 71 patients enrolled in the OLYMPUS trial, 42 patients achieved CR 4 to 6 weeks after completing ≥ 1 instillation of UGN-101. Among the 41 patients followed after initial CR, median follow-up was 28.1 months (95% CI, 13.1-57.5), and median duration of response was 47.8 months (95% CI, 13.0-not estimable [NE]). Twenty patients (49%) had long-term follow-up (median 53.3 months [95% CI, 27.9-65.3]). Seventy-five percent of patients had no evidence of recurrence at the last follow-up, with median duration of response NE (95% CI, 43.5-NE) because of a low event rate. CONCLUSIONS: Primary intracavitary chemoablation with UGN-101 for low-grade upper tract urothelial carcinoma is associated with favorable long-term durability.
引用
- Pierorazio PM, Kleinmann N, Shabsigh A, et al. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J Urol. 2024. PMID: 39561384. doi:10.1097/JU.0000000000004331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。